Skip to content
Lynparza(olaparib)
Lynparza (olaparib) is a small molecule pharmaceutical. Olaparib was first approved as Lynparza on 2014-12-16. It is used to treat ovarian neoplasms in the USA. It has been approved in Europe to treat ovarian neoplasms. The pharmaceutical is active against poly [ADP-ribose] polymerase 2 and poly [ADP-ribose] polymerase 1. In addition, it is known to target poly [ADP-ribose] polymerase tankyrase-1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
endocrine system diseasesD004700
Trade Name
FDA
EMA
Lynparza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Olaparib
Tradename
Company
Number
Date
Products
LYNPARZAAstraZenecaN-208558 RX2017-08-17
2 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
lynparzaNew Drug Application2021-03-11
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
ovarian neoplasmsEFO_0003893D010051C56
Agency Specific
FDA
EMA
Expiration
Code
OLAPARIB, LYNPARZA, ASTRAZENECA
2027-05-08ODE-306
2026-12-27ODE-283
2025-12-19ODE-226
2025-03-11I-885
2024-08-17ODE-180, ODE-181
2023-05-19I-832
2023-05-08I-831
Patent Expiration
Patent
Expires
Flag
FDA Information
Olaparib, Lynparza, Astrazeneca
88595622031-08-04U-1634, U-2101, U-2103, U-2480, U-2482, U-2483, U-2716, U-2819, U-2820, U-2821, U-2822, U-2823, U-2824, U-2832, U-2833, U-3333
84758422029-12-31DP
82474162028-09-24DP
80715792027-08-12U-2101, U-2103, U-2480, U-2482, U-2483, U-2716, U-2819, U-2820, U-2821, U-2822, U-2823, U-2824, U-2832, U-2833, U-3333
81432412027-08-12U-1634, U-2101, U-2103, U-2480, U-2482, U-2483, U-2716, U-2819, U-2820, U-2821, U-2822, U-2823, U-2824, U-2832, U-2833, U-3333
74494642024-10-11DS, DP
79818892024-10-11DS, DP
89121872024-03-12U-1634, U-2101, U-2480, U-2482, U-2483, U-2819, U-2820, U-2821, U-2822, U-2823, U-2824, U-3333
91692352024-03-12U-2832, U-2833
95662762024-03-12U-2716
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XK: Poly (adp-ribose) polymerase (parp) inhibitors
— L01XK01: Olaparib
HCPCS
No data
Clinical
Clinical Trials
363 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ovarian neoplasmsD010051EFO_0003893C562438151877
Breast neoplasmsD001943EFO_0003869C50273761162
NeoplasmsD009369C801814—1232
Castration-resistant prostatic neoplasmsD06412971631—21
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Triple negative breast neoplasmsD06472610171——24
Prostatic neoplasmsD011471C617181——23
Pancreatic neoplasmsD010190EFO_0003860C258141——21
Fallopian tube neoplasmsD0051858103——17
Non-small-cell lung carcinomaD002289592——14
Endometrial neoplasmsD016889EFO_0004230572—112
Stomach neoplasmsD013274EFO_0003897C16491——10
Small cell lung carcinomaD055752561——10
Endometrioid carcinomaD018269372——9
Colorectal neoplasmsD015179251——7
Show 6 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Squamous cell carcinoma of head and neckD00007719544———7
AdenocarcinomaD00023017———7
Non-hodgkin lymphomaD008228C85.924———6
GliomaD005910EFO_000052016———6
GlioblastomaD005909EFO_000051523———5
Urinary bladder neoplasmsD001749C6714———5
Renal cell carcinomaD00229213———4
Pancreatic ductal carcinomaD02144113———4
CholangiocarcinomaD018281C22.1—4———4
Multiple myelomaD009101C90.012———3
Show 50 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hodgkin diseaseD006689C812————2
Neoplasm metastasisD009362EFO_00097082————2
Head and neck neoplasmsD0062582————2
Squamous cell neoplasmsD0183072————2
LymphomaD008223C85.92————2
Hematologic neoplasmsD0193371————1
Primary myelofibrosisD055728D47.41————1
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.01————1
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_00003401————1
Myelomonocytic leukemia chronicD015477C93.11————1
Show 8 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOLAPARIB
INNolaparib
Description
Olaparib is a member of the class of N-acylpiperazines obtained by formal condensation of the carboxy group of 2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]benzoic acid with the free amino group of N-(cyclpropylcarbonyl)piperazine; used to treat advanced ovarian cancer. It has a role as an antineoplastic agent, an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor and an apoptosis inducer. It is a N-acylpiperazine, a member of cyclopropanes, a member of monofluorobenzenes and a member of phthalazines.
Classification
Small molecule
Drug classpoly-ADP-ribose polymerase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1
Identifiers
PDB7KKO
CAS-ID763113-22-0
RxCUI1597582
ChEMBL IDCHEMBL521686
ChEBI ID83766
PubChem CID23725625
DrugBankDB09074
UNII IDWOH1JD9AR8 (ChemIDplus, GSRS)
Target
Agency Approved
PARP2
PARP2
PARP1
PARP1
Organism
Homo sapiens
Gene name
PARP2
Gene synonyms
ADPRT2, ADPRTL2
NCBI Gene ID
10038
Protein name
poly [ADP-ribose] polymerase 2
Protein synonyms
ADP-ribosyltransferase (NAD+; poly(ADP-ribose) polymerase)-like 2, ADP-ribosyltransferase diphtheria toxin-like 2, ADPRT-2, ARTD2, DNA ADP-ribosyltransferase PARP2, hPARP-2, NAD(+) ADP-ribosyltransferase 2, pADPRT-2, poly (ADP-ribose) polymerase family, member 2, poly (ADP-ribosyl) transferase-like 2, Poly[ADP-ribose] synthase 2, poly[ADP-ribose] synthetase 2, Protein poly-ADP-ribosyltransferase PARP2
Uniprot ID
Q9UGN5
Mouse ortholog
Parp2 (11546)
poly [ADP-ribose] polymerase 2 (Q99N29)
Alternate
TNKS
TNKS
Organism
Homo sapiens
Gene name
TNKS
Gene synonyms
PARP5A, PARPL, TIN1, TINF1, TNKS1
NCBI Gene ID
8658
Protein name
poly [ADP-ribose] polymerase tankyrase-1
Protein synonyms
ADP-ribosyltransferase diphtheria toxin-like 5, ARTD5, Poly [ADP-ribose] polymerase 5A, Protein poly-ADP-ribosyltransferase tankyrase-1, TANK1, Tankyrase I, tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase, Tankyrase-1, TNKS-1, TRF1-interacting ankyrin-related ADP-ribose polymerase, TRF1-interacting ankyrin-related ADP-ribose polymerase 1
Uniprot ID
Q59FX0
Mouse ortholog
Tnks (21951)
poly [ADP-ribose] polymerase tankyrase-1 (Q8BX62)
Variants
Clinical Variant
No data
Financial
Lynparza - AstraZeneca
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Lynparza - Merck Sharp & Dohme
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 13,894 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details